Project Grant R01AG096298
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Icahn School of Medicine at Mount Sinai a $8.07 million Project Grant under the Aging Research program (CFDA 93.866) on September 15, 2025, for a five-year project period extending through August 31, 2030. This research initiative examines unique markers and risk factors for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) in foreign- and native-born older Chinese Americans through an...
- Federal Grant Award Summary The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai a $839,933 Project Grant under the Aging Research program (CFDA 93.866) to investigate the role of N6-methyladenosine (M6A) RNA modifications in microglial dysfunction and Alzheimer's disease pathogenesis. The five-year research project, which commenced September 1, 2025 and concludes May 31, 2030, will systematically map M6A RNA modification landscapes in microglia isolated from human...
- Federal Project Grant Award Summary The National Institute on Aging (Aging Research program, CFDA 93.866) awarded Icahn School of Medicine at Mount Sinai $835,417 in project grant funding effective June 1, 2025, through March 31, 2030. This award supports the development and evaluation of novel lipid nanoparticle (LNP)-based RNA therapeutics targeting apolipoprotein E (APOE) regulation for Alzheimer's disease treatment. The research encompasses synthesis of blood-brain barrier (BBB)-crossing...
- Federal Grant Award Summary The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai a $615,602 Project Grant effective September 20, 2025, through May 31, 2030, under the Aging Research program (CFDA 93.866). The Postbaccalaureate Alzheimer's Disease Development Initiative (PADDI) is a comprehensive two-year training program designed to address the lack of ethnic and racial diversity among research personnel in Alzheimer's Disease and Related Disorders (ADRD) research....
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Icahn School of Medicine at Mount Sinai a $3.55 million Project Grant under the Aging Research program (CFDA 93.866) effective September 1, 2025 through August 31, 2029. This award supports scientific research investigating the relationship between individual stress vulnerability and the emergence of neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD). The research employs mouse models to examine how...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $336,000 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with completion targeted for August 31, 2027. This research initiative evaluates the utility of self-reported subjective cognitive concerns (SCC) as an early screening tool for Alzheimer's disease (AD) by examining their relationship with longitudinal AD biomarkers in a diverse...
- Federal Grant Award Summary The National Institute on Aging awarded a $610,836 Project Grant to the Broad Institute of MIT and Harvard (effective September 1, 2025, through May 31, 2030) under the Aging Research program (CFDA 93.866) to conduct systematic genetic research on mitonuclear interactions in aging and neurodegenerative diseases. The research will leverage two technological advances—mitochondrial DNA (mtDNA) editing using DDCBE base editors and biobank-scale analysis of mtDNA copy...
- This $745,765 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York aims to investigate the effects of Alzheimer's disease (AD) risk genes and aging on human microglia activity and lipid metabolism. The key focus is on understanding how genetic variants associated with increased AD risk or longevity may impact microglia's ability to clear cholesterol/lipid-rich cellular debris, a critical...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $2.13 million to Icahn School of Medicine at Mount Sinai under the Aging Research program (CFDA 93.866) to develop and validate novel adeno-associated virus (AAV) constructs for gene therapy targeting Alzheimer's disease in postmenopausal women. The research focuses on engineering AAV vectors carrying cell-specific enhancers to enable targeted knockdown of follicle-stimulating hormone receptor (FSHR) in neurons...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $127,224 to the University of California, San Diego on October 24, 2025, under the Aging Research program (CFDA 93.866) to support scientific investigation into the pathological mechanisms of Alzheimer's disease (AD). The project, which extends through August 31, 2028, will elucidate the role of s-nitrosylated phospholipase D3 (SNO-PLD3) in microglial and neuronal pathophysiology associated with AD. Specifically,...
The National Institute on Aging awarded a $575,377 Project Grant to Icahn School of Medicine at Mount Sinai on February 15, 2026, under the Aging Research program (CFDA 93.866). This research project, extending through November 30, 2030, investigates the elevated risk of Alzheimer's Disease and Related Dementias (ADRD) among individuals with Autism Spectrum Disorder (ASD). The study leverages multiple national health registries—including Swedish National Health Registries (>5 million individuals), U.S. healthcare databases (>100 million individuals), and Israeli registries (>1.6 million individuals)—to establish the epidemiological association between ASD and early-onset ADRD, identify contributing risk factors such as cardiometabolic disorders and depression, and explore underlying genetic mechanisms. The research team will conduct comparative analyses across these geographically diverse populations to validate findings and assess generalizability of results. The project delivers comprehensive research services focused on characterizing the aging process in ASD populations and understanding disease etiology. Key deliverables include epidemiological analyses examining ADRD risk trajectories across international cohorts, identification of critical pathogenic factors, and investigation of familial clustering patterns to elucidate genetic contributions. This research addresses an urgent public health need given the impending aging of the large ASD population and anticipated societal costs associated with increased ADRD prevalence in this vulnerable subgroup.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $575.4k | 2/6/26 |